Introduction

The Cycloph 1g (Cyclophosphamide) Injection is a high-potency alkylating chemotherapy agent designed for aggressive treatment of advanced hematologic malignancies and solid tumors, including Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, leukemia, and carcinomas of the breast, ovary, and bladder. Manufactured by Eskayef Pharmaceuticals Ltd., a global leader in oncology innovation, and supplied by Onco Solution, a trusted provider of life-saving cancer therapies, this 1g formulation delivers intensified DNA cross-linking action to disrupt cancer cell proliferation. Ideal for patients with bulky or refractory tumors, Cycloph 1g combines robust efficacy with stringent safety protocols for advanced cancer management.

Key Benefits

• High-Potency Dosing: 1g/vial for optimal dosing in aggressive or treatment-resistant cancers.
• Broad-Spectrum Efficacy: Effective against lymphomas, leukemias, multiple myeloma, and solid tumors.
• Combination Synergy: Enhances outcomes when paired with immunotherapy, radiotherapy, or targeted therapies.

Indications

The Cycloph 1g (Cyclophosphamide) Injection is indicated for:

• Malignant Lymphomas: Hodgkin’s disease, Burkitt’s lymphoma, diffuse large B-cell lymphoma.
• Leukemias: Acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL).
• Solid Tumors: Breast carcinoma, ovarian adenocarcinoma, neuroblastoma, retinoblastoma.
• Multiple Myeloma and Mycosis Fungoides (advanced stages).

Pharmacology

• Mechanism of Action: Cyclophosphamide is metabolized in the liver into active alkylating metabolites (e.g., phosphoramide mustard), which form DNA cross-links, blocking replication and inducing apoptosis in rapidly dividing cancer cells.
• Synergy: Potentiates the effects of monoclonal antibodies (e.g., rituximab) and checkpoint inhibitors.

Dosage & Administration

Malignant Diseases (Adults & Pediatrics)

• Intravenous Monotherapy:
  • Initial Dose: 40–50 mg/kg divided over 2–5 days (e.g., 1g daily for 4 days in a 70 kg patient).
  • Alternative Regimens:
    • 10–15 mg/kg every 7–10 days.
    • 3–5 mg/kg twice weekly.
• Combination Therapy: Reduce dose by 20–30% when used with other cytotoxic drugs.

Preparation & Handling

• Reconstitution:
  • Direct IV Injection: Dilute to 20 mg/mL using 0.9% NaCl, 0.45% NaCl, or 5% dextrose.
    • Example: 1g vial + 50 mL diluent.
  • IV Infusion: Dilute to 2 mg/mL with the same solutions.
    • Example: 1g vial + 500 mL diluent.
• Administration:
  • Infuse slowly over 60–120 minutes to minimize adverse reactions (e.g., facial swelling, hypotension).
  • Avoid Sterile Water for Injection (risk of hypotonic hemolysis).

Storage

• Unopened Vials: Store at 25°C; protect from light.
• Reconstituted Solution:
  • Refrigerate at 2–8°C (36–46°F) for up to 28 days.
  • Discard unused portions after 28 days.

Contraindications

• Hypersensitivity to cyclophosphamide or its components.
• Severe renal impairment (eGFR < 30 mL/min) or urinary obstruction.

Side Effects

Common Reactions:

• Hematologic: Severe neutropenia (nadir at 7–14 days), thrombocytopenia, anemia.
• Gastrointestinal: Nausea, vomiting (manage with 5-HT3 antagonists), diarrhea.
• Dermatologic: Alopecia (reversible post-treatment), nail discoloration.

Serious Risks:

• Myelosuppression: Life-threatening infections (e.g., sepsis, pneumonia).
• Cardiotoxicity: Acute myocarditis, arrhythmias.
• Pulmonary Toxicity: Interstitial pneumonitis, respiratory failure.
• Secondary Malignancies: Increased risk of bladder cancer and myelodysplasia.

Warnings & Precautions

1. Hydration Protocol:
   • Administer 2–3 liters of IV fluid daily to prevent hemorrhagic cystitis.
   • Monitor urine output and renal function (creatinine, electrolytes).
2. Infection Control:
   • Prophylactic granulocyte colony-stimulating factor (G-CSF) for neutropenia.
3. Cardiac Monitoring:
   • Baseline and periodic echocardiograms for high-risk patients.
4. Fertility Preservation:
   • Offer sperm/egg cryopreservation due to risk of permanent infertility.

Adverse Reactions

• Hepatotoxicity: Veno-occlusive disease (monitor LFTs).
• Neurologic: Hyponatremia (correct with hypertonic saline if severe).
• Reproductive: Ovarian/testicular failure, teratogenicity (Pregnancy Category D).

Use in Specific Populations

• Pregnancy: Contraindicated. Use dual contraception during and for 1 year post-treatment.
• Lactation: Discontinue breastfeeding due to risks of infant immunosuppression.
• Renal Impairment: Dose reduction required for eGFR < 60 mL/min.

Why Choose Cycloph 1g (Cyclophosphamide) Injection?

• High-Potency Efficacy: Critical for aggressive or refractory malignancies.
• Trusted Manufacturer: Produced by Eskayef Pharmaceuticals Ltd., a pioneer with 30+ years in oncology excellence.
• Global Accessibility: Supplied by Onco Solution, ensuring equitable access across Asia, Africa, and Europe.

Technical Specifications

• Active Ingredient: Cyclophosphamide USP (1g/vial).
• Packaging: Lyophilized powder in sterile, tamper-evident vials.
• Shelf Life: 24 months (unopened).

Commitment to Excellence

Eskayef Pharmaceuticals Ltd., part of Bangladesh’s Transcom Group, combines cutting-edge research with uncompromising quality control. Partnering with Onco Solution, they deliver life-saving therapies to underserved regions, prioritizing affordability and patient-centric care.

Conclusion

The Cycloph 1g (Cyclophosphamide) Injection is a pivotal therapy in advanced oncology, offering high-potency DNA-targeted action for aggressive malignancies. By integrating this alkylating agent into treatment regimens, clinicians leverage a trusted solution backed by Eskayef Pharmaceuticals Ltd. and Onco Solution – global leaders in cancer care innovation.